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Background: Albuminuria has been classically considered a marker of kidney damage progression in diabetic patients
and it is routinely assessed to monitor kidney function. However, the role of a mild GFR reduction on the development
of stage ≥3 CKD has been less explored in type 1 diabetes mellitus (T1DM) patients. Aim of the present study was to
evaluate the prognostic role of kidney disease measures, namely albuminuria and reduced GFR, on the development of
stage ≥3 CKD in a large cohort of patients affected by T1DM.
Methods: A total of 4284 patients affected by T1DM followed-up at 76 diabetes centers participating to the
Italian Association of Clinical Diabetologists (Associazione Medici Diabetologi, AMD) initiative constitutes the
study population. Urinary albumin excretion (ACR) and estimated GFR (eGFR) were retrieved and analyzed.
The incidence of stage ≥3 CKD (eGFR < 60mL/min/1.73 m2) or eGFR reduction > 30% from baseline was evaluated.
Results: The mean estimated GFR was 98 ± 17 mL/min/1.73m2 and the proportion of patients with albuminuria
was 15.3% (n = 654) at baseline. About 8% (n = 337) of patients developed one of the two renal endpoints during the
4-year follow-up period. Age, albuminuria (micro or macro) and baseline eGFR < 90ml/min/m2 were independent risk
factors for stage ≥3 CKD and renal function worsening. When compared to patients with eGFR > 90ml/min/1.73m2
and normoalbuminuria, those with albuminuria at baseline had a 1.69 greater risk of reaching stage 3 CKD,
while patients with mild eGFR reduction (i.e. eGFR between 90 and 60 mL/min/1.73 m2) show a 3.81 greater
risk that rose to 8.24 for those patients with albuminuria and mild eGFR reduction at baseline.
Conclusions: Albuminuria and eGFR reduction represent independent risk factors for incident stage ≥3 CKD
in T1DM patients. The simultaneous occurrence of reduced eGFR and albuminuria have a synergistic effect on
renal function worsening.
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Diabetes represents the primary cause of end-stage renal
disease (ESRD) in most of industrialized Countries [1]. It
plays a synergistic role together with hypertension and
ageing in the pathogenesis of renal disease [2]. The preva-
lence of diabetic nephropathy is constantly increasing [3,* Correspondence: antonio.mirijello@gmail.com; a.mirijello@operapadrepio.it;
s.decosmo@operapadrepio.it
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reduction of Quality of Life (QoL) [5].
Diabetic kidney disease (DKD) is a serious complica-
tion of both forms of diabetes [4], involving about 25–
75% of patients with type 1 diabetes (T1DM) [4, 6] and
about 30–40% of those with type 2 diabetes (T2DM) [4].
Historically DKD has been defined as an increased urin-
ary albumin excretion (i.e. microalbuminuria) that ap-
pears about 5 to 10 years after the onset of diabetes and,
if untreated, progresses, in a period of 10–15 years, to
macroalbuminuria (i.e. proteinuria) and to reducedle is distributed under the terms of the Creative Commons Attribution 4.0
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[4]. Thus, the search and periodic evaluation of microal-
buminuria for the diagnosis and follow-up of diabetic ne-
phropathy has become part of routine clinical practice [7].
However, recent evidence suggests the increasing
prevalence of a different pathway of DKD characterized
by a decline of GFR (even) in the absence of micro and/
or macroalbuminuria [6, 8–10].
Over the last decades, besides the identification of
genetic predisposing factors [3, 11, 12], several environ-
mental determinants [7] for the development and pro-
gression of kidney dysfunction in patients with T1DM
have been described. Among these, hyperglycemia, dys-
lipidemia, increased blood pressure (BP) and smoking
have been emphasized to bear a relevant unfavorable ef-
fect on renal function [6, 9, 13, 14].
In patients with T1DM, increased levels of albumin-
uria are not only a well-known manifestation of diabetic
renal involvement, but also an established marker of
renal damage progression. Longitudinal studies have
demonstrated that GFR declines in parallel with the in-
crease in urinary albumin excretion and Perkins and
co-workers have shown a significant correlation between
the rate of GFR decline with progressive stages of albu-
minuria [15]. In this context, the role of a mild, isolated
GFR reduction on the development of stage ≥3 CKD has
been less explored in T1DM patients.
Aim of the present study was to evaluate the inde-
pendent prognostic role of kidney disease measures,
namely albuminuria and reduced GFR, on the develop-
ment of stage ≥3 CKD in a large cohort of patients af-
fected by T1DM.
Methods
Study setting, patients and data sources
The study population is represented by patients affected
by T1D followed-up at 155 Italian diabetes centers partici-
pating to the Italian Association of Clinical Diabetologists
initiative (Associazione Medici Diabetologi, AMD). Elec-
tronic medical records collected between January 2004
and June 2008 were analyzed. Data set of patients ≥18
years old, with a follow-up within 48 ± 6months, and no
missing data concerning BP values, estimated GFR
(eGFR), baseline evaluation of HbA1c, albuminuria classi-
fication, triglycerides, HDL and LDL were evaluated.
Of 6298 patients identified, 2014 have been excluded
for the reasons showed in Fig. 1.
The final study population is represented by 4284 pa-
tients affected by T1DM from 76 clinics homogeneously
distributed throughout the Country.
Methods and data collection
As previously reported [6, 9, 16–19], the Italian Association
of Clinical Diabetologists (Associazione Medici Diabetologi,AMD) initiative and its clinical database were set up to
recognize a set of indicators to be used for continuous qual-
ity improvement. The software for medical management of
outpatients is the same among all centers. Patients’ data re-
corded are anonymized under a unique identification ID,
encrypted to protect patients’ privacy. Clinical information
collected from all centers can be anonymously extracted
and centrally analyzed (AMD Data File) [16–19]. The auto-
mated system prevents the identification of individual pa-
tients. Thus, according to Italian law ethical committee
approval and informed consent were not required. Results
were internally revised and approved by AMD Annals Sci-
entific Committee.
This initiative includes the measurement and moni-
toring of HbA1c, BP, low-density lipoprotein (LDL-c),
total and high density lipoprotein cholesterol (HDL-c)
and triglycerides, together with the evaluation of the
use of specific classes of drugs (insulin, statins and two
or more anti-hypertensive agents). Given the variability
of normal ranges among centers, in order to allow
comparisons, the estimated percentage change (mea-
sured value/upper normal limit) was multiplied by 6.0.
The measurement of TG, performed by enzymatic-
colorimetric or by ORTHO instrumentation had the
same normal range. Even for HDL-C, normal range and
decisional levels were the same.
Serum creatinine and urinary albumin excretion were
used to assess kidney function. GFR was estimated by
using a standardized serum creatinine assay and the
Chronic Kidney Disease Epidemiology Collaboration for-
mula [20]. Increased urinary albumin excretion was di-
agnosed as: i. microalbuminuria if urinary albumin
concentration was > 30 and ≤ 300 mg/L, or if urinary al-
bumin excretion rate was > 20 and ≤ 200 μg/min, or if
urinary albumin-to-creatinine ratio (ACR) was > 2.5 mg/
mmol in men and > 3.5 mg/mmol in women and ≤ 30
mg/mmol in both gender; ii. macroalbuminuria if urin-
ary albumin concentration was > 300 mg/L, or if urinary
albumin excretion rate was > 200 μg/min, or if ACR was
> 30mg/mmol in both gender. Albuminuria indicates
patients with either micro or macroalbuminuria. In the
present study, albuminuria determination was based on
a single issue [21].
Physical examination and BP measurement were per-
formed by a standardized protocol [6, 9, 16–19].
DKD was defined as diabetes with albuminuria or low
eGFR (i.e. < 60 mL/min/1.73 m2) or both.Renal outcomes
The outcomes were: i. stage ≥3 CKD, i.e. an eGFR < 60
mL/min/1.73 m2; ii. eGFR reduction > 30% as compared
to baseline; iii. The combination of either one of the two
previous endpoints.
Fig. 1 Study population: inclusion and exclusion criteria
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Data are given as mean values ± standard deviation
(SD); categorical variables are described as frequencies
and percentages. Linear and logistic regression models
were used to evaluate variables associated to, respect-
ively, continuous and categorical data. To consider pos-
sible differences in data across diabetes clinics, mixed
models were fitted with the enrolling centers as random
effect. For each renal outcome were reported odds ratios
(ORs) with their 95% confidence intervals (95% CIs).
Multivariate models were fitted including a missing indi-
cator variable (for BMI) and a complete-case analysis
was also performed including only patients with all data
available (models including serum uric acid and smoke
status). The analyses were made using STATA software,
version 14 (StataCorp, College Station, Texas). P values
of < 0.05 were considered statistically significant.
Results
Table 1 summarizes the main clinical features of the
study population at baseline, overall and on the basis of
the presence/absence of albuminuria. Table 2 summa-
rizes the number and percentage of patients who
reached one of the renal outcome at 4 year follow-up
(Table 2).
The mean age was 45 ± 14 years (56.8% male). Mean
diabetes duration was 18 ± 12 years. The glyco-metabolic
status of participants was rather unfair, being the mean
values of HbA1c and LDL-c of 7.8 ± 1.4% and 110 ± 31
mg/dL, respectively. The average BP was 126 ± 17/76 ±
9mmHg; about 30.6% of patients had BP > 140/85
mmHg at baseline. More than a quarter of patients were
receiving antihypertensive treatment and 23.4% weretaking an ACE-I or an ARB. The mean eGFR was 98 ±
17mL/min/1.73 m2 and the proportion of patients with
albuminuria was 15.3% (n = 654). Patients showing base-
line albuminuria had a worse risk profile, such as longer
duration of disease, higher BMI, serum uric acid,
HbA1c, a more atherogenic lipid profile (i.e. higher tri-
glycerides and LDL values). Moreover, they showed
higher BP despite more antihypertensive and lipid lower-
ing treatments.
Additional file 1: Table S1 reports the baseline
clinical features of patients grouped on the basis of
the achieved renal outcome within the study period.
On average, patients who went on to develop low
eGFR (i.e. < 60/ml/min/1.73m2 or eGFR reduction > 30%)
showed a worse clinical profile. Older age, longer
duration of diabetes and worse glycemic control were
associated with the achievement of both renal out-
comes while baseline eGFR was lower only among
patients who developed stage ≥3 CKD. Patients who
developed stage ≥3 CKD showed also significantly
higher BP values at baseline, despite a higher preva-
lence of antihypertensive treatment, even with ACE-I
or ARB.
The cumulative number of patients with a first occur-
rence of any of the two renal endpoints steadily in-
creased during the study period (Fig. 2 a-c), with an
incidence of 2.12% per year. Of the 4284 evaluated pa-
tients, 238 patients (5.6%) developed stage > 3 CKD
within the 4-year follow-up period (Table 2 and Fig. 2a),
while 215 patients (5%) showed a > 30% decrease in
eGFR as compared to baseline (Table 2 and Fig. 2b) and
337 patients (7.9%) shower the combination of these two
endpoints (Table 2 and Fig. 2c).
Table 2 Four-year renal outcome of patients grouped by the presence of albuminuria
All Normoalbuminuria Microalbuminuria Macroalbuminuria p
n = 4284 n = 3630 n = 557 n = 97
GFR < 60 mL/min/1.73 m2 238 (5.6%) 175 (4.8%) 43 (7.7%) 20 (20.6%) < 0.001
GFR reduction > 30% than baseline 215 (5.0%) 154 (4.2%) 42 (7.5%) 19 (19.6%) < 0.001
GFR < 60 or reduction > 30% 337 (7.9%) 255 (7.0%) 56 (10.1%) 26 (26.8%) < 0.001
Table 1 Baseline clinical characteristics of patients grouped by the presence of albuminuria
All Normoalbuminuria Microalbuminuria Macroalbuminuria p
n = 4284 n = 3630 n = 557 n = 97
Male sex 2432 (56.8%) 2009 (55.3%) 363 (65.2%) 60 (61.9%) < 0.001
Age (years) 45 ± 14 44 ± 14 47 ± 14 48 ± 12 0.006
Known duration of diabetes (years) 18 ± 12 17 ± 12 20 ± 12 25 ± 11 < 0.001
BMI (Kg/m2) 24.5 ± 3.6 24.4 ± 3.5 25.0 ± 3.7 25.4 ± 3.8 0.003
Serum creatinine (mg/dL) 0.84 ± 0.17 0.84 ± 0.16 0.86 ± 0.17 0.91 ± 0.21 < 0.001
eGFR (mL/min/1.73 m2) 98 ± 17 99 ± 17 96 ± 16 91 ± 18 < 0.001
Serum uric acid (mg/dL) 3.9 ± 1.4 3.8 ± 1.4 4.2 ± 1.2 4.6 ± 1.2 < 0.001
Serum uric acid in the top quintile 447 (18.3%) 361 (17.0%) 65 (24.5%) 21 (40.4%) < 0.001
HbA1c (%) 7.8 ± 1.4 7.7 ± 1.4 8.0 ± 1.4 8.3 ± 1.4 < 0.001
HbA1c≥ 7% 3071 (71.7%) 2555 (70.4%) 435 (78.1%) 81 (83.5%) 0.001
Total cholesterol (mg/dL) 190 ± 36 189 ± 35 188 ± 38 205 ± 42 < 0.001
Triglycerides (mg/dL) 87 ± 79 85 ± 81 97 ± 64 117 ± 70 < 0.001
Triglycerides ≥150mg/dl 360 (8.4%) 275 (7.6%) 65 (11.7%) 20 (20.6%) < 0.001
HDL (mg/dL) 62 ± 18 62 ± 18 60 ± 19 61 ± 17 0.089
HDL < 40 M <50F mg/dL 501 (11.7%) 408 (11.2%) 80 (14.4%) 13 (13.4%) 0.208
LDL (mg/dL) 110 ± 31 110 ± 31 109 ± 32 121 ± 35 0.001
LDL ≥100 mg/dL 2638 (61.6%) 2244 (61.8%) 324 (58.2%) 70 (72.2%) 0.012
Systolic BP (mmHg) 126 ± 17 125 ± 17 130 ± 19 137 ± 22 < 0.001
Diastolic BP (mmHg) 76 ± 9 75 ± 9 77 ± 9 80 ± 11 < 0.001
BP ≥ 140/85mmHg 1310 (30.6%) 1039 (28.6%) 218 (39.1%) 53 (54.6%) < 0.001
Non-proliferative retinopathy 925 (21.6%) 744 (20.5%) 149 (26.8%) 32 (33.0%) 0.018
Proliferative retinopathy 321 (7.5%) 232 (6.4%) 72 (12.9%) 17 (17.5%) < 0.001
Smokers 602 (27.9%) 515 (27.3%) 72 (31.6%) 15 (38.5%) 0.119
Lipid-lowering treatment 861 (20.1%) 664 (18.3%) 162 (29.1%) 35 (36.1%) < 0.001
Treatment with statins 822 (19.2%) 638 (17.6%) 153 (27.5%) 31 (32.0%) < 0.001
Treatment with fibrates 19 (0.4%) 13 (0.4%) 4 (0.7%) 2 (2.1%) 0.045
Antihypertensive treatment 1102 (25.7%) 779 (21.5%) 249 (44.7%) 74 (76.3%) < 0.001
Treatment with ACE-Is/ARBs 1001 (23.4%) 699 (19.3%) 231 (41.5%) 71 (73.2%) < 0.001
Aspirin 425 (9.9%) 310 (8.5%) 93 (16.7%) 22 (22.7%) < 0.001
Insulin pump 304 (7.1%) 269 (7.4%) 29 (5.2%) 6 (6.2%) 0.563
Mean ± SD or absolute frequency (percentage). BMI body mass index, BP blood pressure, HbA1c glycated haemoglobin, HDL high-density lipoprotein cholesterol,
LDL low-density lipoprotein cholesterol, eGFR estimated glomerular filtration rate, SBP systolic blood pressure, DBP diastolic blood pressure, ACE-Is angiotensin
converting enzyme-inhibitors, ARBs angiotensin II receptor antagonists. Patients’ baseline missing data: BMI in 176 (4.1%), serum uric acid in 1847 (43.1%), total
cholesterol in 58 (1.4%), and smoking status in 2128 (49.7%). Serum uric acid the top gender-specific quintile: ≥4.0 mg/dL for females and ≥ 5.1 mg/dL for males.
The p value refers to overall statistical significance of a mixed logistic regression model for categorical variables or mixed linear regression model for continuous
variables with microalbuminuria and macroalbuminuria as covariate
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Fig. 2 Year cumulative incidence of anyone of the two renal endpoints
((a) eGFR< 60mL/min/1.73m2; (b) eGFR reduction > 30% from baseline;
(c) both endpoints) during 4-year follow-up
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macro) and baseline eGFR < 90ml/min/m2 remained in-
dependently and significantly associated to a higher risk of
incident stage > 3 CKD and renal function worsening
(Table 3). The duration of diabetes, BMI, baseline HbA1c
and BP values did not significantly influence the outcome
(Table 3). As for lipid profile, neither HDL nor LDL chol-
esterol levels significantly influence the outcome. On the
contrary, a significant association with higher TG levels
and eGFR reduction > 30% at 4-years was found (Table 3).
To better investigate the role of albuminuria and eGFR
values on renal outcomes, patients were stratified basedon the baseline eGFR (> 90 / 60–90) and albuminuria
(Alb+/Alb-) (Fig. 3a, Additional file 2: Table S2). Among
patients with eGFR values above or below 90ml/min/
1.73 m2 albuminuria was present in 15.9 and 23.2%, re-
spectively (Additional file 2: Table S2). With respect to
patients with eGFR > 90ml/min/1.73m2 and normoalbu-
minuria (reference), the OR of developing the composite
renal endpoint over 4-year study period was 1.69 (95%CI
1.08–2.64; p = 0.021) for patients with albuminuria and
baseline eGFR values above 90mL/min and rose pro-
gressively to 3.81 (95%CI 2.91–4.99; p < 0.001) in pa-
tients with normal albumin and eGFR values between 90
and 60 mL/min and then further up to 8.24 (95%CI
5.57–12.17; p < 0.001) when albuminuria was concomi-
tant to mild GFR reduction (i.e. GFR between 90 and 60
mL/min) (Fig. 3b).
Figure 4 shows the estimated worsening rate of renal
function at any given baseline eGFR. Albuminuria ap-
pears as an adjunctive risk factor for the progression to
stage > 3 CKD over the entire study period.
Multivariate OR for the incidence of stage > 3 CKD in
patients with a given baseline eGFR and without albu-
minuria are showed in Fig. 5.
Discussion
The present study shows that the cumulative inci-
dence of stage ≥3 CKD observed over a 4-year
follow-up in a large sample of patients affected by
T1DM, representative of real-life Italian clinical prac-
tice, is 5.6%. In addition, both albuminuria and mild
eGFR reduction independently predict a significant
decline of renal function.
The observed rate of onset of stage ≥3 DKD is consist-
ent with that previously reported in other cohorts of pa-
tients with similar characteristics [22–25].
Overall, patients who went on to develop stage > 3
CKD were older and had an unfavorable cardiovascular
risk profile at baseline as compared to patients who did
not develop renal dysfunction. The former, in fact, had a
worse glycemic control, a more atherogenic lipid profile
(i.e. lower HDL cholesterol and higher triglycerides), and
higher levels of systolic and diastolic blood pressure des-
pite the presence of a more aggressive antihypertensive
treatment. Finally, micro or macroalbuminuria were
more prevalent among patients who developed stage ≥3
CKD, who had also a lower baseline eGFR value.
In the present work, we have focused on the distinct
role of albuminuria and mild eGFR reduction in promot-
ing the onset of stage ≥3 CKD. In our dataset, albumin-
uria (i.e. micro or macroalbuminuria) appears to be a
strong and independent predictor of kidney function
loss. These data confirm and expand previous seminal
observation by Viberti and co-workers [26] who first de-
scribed the role of microalbuminuria as marker of early
Table 3 Multivariate analysis of renal outcome within 4-year
eGFR < 60 mL/min/1.73 m2 eGFR reduction > 30% than
baseline
eGFR < 60 mL/min/1.73 m2 or
reduction > 30%
Odds Ratio (95%CI) p Odds Ratio (95%CI) p Odds Ratio (95%CI) p
Male sex 0.9 (0.65–1.24) 0.512 0.53 (0.39–0.71) < 0.001 0.59 (0.46–0.76) < 0.001
Age (by 10 years) 1.91 (1.65–2.22) < 0.001 1.38 (1.21–1.58) < 0.001 1.46 (1.30–1.63) < 0.001
Duration of diabetes (by 5 years) 0.95 (0.89–1.01) 0.107 1.01 (0.94–1.08) 0.819 0.98 (0.93–1.04) 0.500
BMI
27–30 Kg/m2 0.93 (0.61–1.43) 0.754 1.02 (0.68–1.53) 0.924 1.09 (0.77–1.53) 0.636
> 30 Kg/m2 1.16 (0.67–2.02) 0.599 0.92 (0.52–1.63) 0.770 1.15 (0.73–1.81) 0.543
Albuminuria
Microalbuminuria 1.55 (1.00–2.40) 0.048 1.87 (1.27–2.76) 0.002 1.44 (1.01–2.06) 0.045
Macroalbuminuria 4.30 (2.19–8.46) < 0.001 5.12 (2.81–9.35) < 0.001 4.09 (2.33–7.16) < 0.001
eGFR below 90mL/min/1.73 m2 (by 5) 1.79 (1.64–1.96) < 0.001 0.87 (0.78–0.97) 0.014 1.46 (1.36–1.57) < 0.001
HbA1c≥ 7% 1.08 (0.73–1.60) 0.695 1.17 (0.82–1.66) 0.386 1.13 (0.83–1.53) 0.437
Triglycerides ≥150mg/dl 1.48 (0.88–2.50) 0.139 2.00 (1.28–3.12) 0.002 1.84 (1.24–2.74) 0.003
HDL < 40 M <50F mg/dL 0.83 (0.50–1.39) 0.480 1.09 (0.71–1.68) 0.695 1.04 (0.71–1.52) 0.835
LDL ≥100mg/dL 1.08 (0.78–1.49) 0.651 0.83 (0.62–1.12) 0.229 0.93 (0.72–1.21) 0.596
BP≥ 140/85 mmHg 1.12 (0.81–1.55) 0.503 1.35 (0.98–1.85) 0.064 1.24 (0.95–1.61) 0.118
Non-proliferative retinopathy 1.09 (0.75–1.58) 0.656 0.76 (0.52–1.10) 0.150 0.86 (0.63–1.17) 0.345
Proliferative retinopathy 1.42 (0.87–2.31) 0.162 1.19 (0.74–1.93) 0.477 1.18 (0.78–1.78) 0.443
Lipid-lowering treatment 0.87 (0.61–1.25) 0.464 0.85 (0.59–1.22) 0.370 0.87 (0.65–1.18) 0.373
Antihypertensive treatment 1.31 (0.90–1.90) 0.155 1.23 (0.86–1.77) 0.256 1.21 (0.90–1.65) 0.211
Aspirin 1.26 (0.83–1.91) 0.273 1.45 (0.95–2.23) 0.089 1.44 (1.01–2.05) 0.046
Insulin pump 1.76 (0.91–3.39) 0.091 0.97 (0.54–1.74) 0.909 1.21 (0.73–1.99) 0.461
Separate models
Serum uric acid (mg/dL) 1.07 (0.96–1.20) 0.211 1.04 (0.94–1.16) 0.460 1.04 (0.95–1.15) 0.393
Serum uric acid in the top quintile 1.44 (0.90–2.31) 0.130 1.20 (0.75–1.89) 0.447 1.29 (0.88–1.90) 0.197
Smokers 0.67 (0.37–1.22) 0.190 1.14 (0.71–1.83) 0.599 0.84 (0.54–1.29) 0.423
Multivariate models were fitted including a missing indicator variable to indicate whether the BMI value is missing. Serum uric acid and smoking status evaluated
in separate models that included patients with complete data
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small sample of patients with T1DM. Perkins and
co-workers [15] several years later have shown among
patients of the Joslin’s T1DM cohort that GFR decline
starts early in the course of microalbuminuria. Recent
results from DCCT by Molitch and co-workers [21] have
further confirmed the role of albuminuria in accelerating
GFR loss among T1DM patients although a not trivial
proportion of patients (i.e. 24%), developed persistent
eGFR < 60ml/min/1.73 m2 in absence of albuminuria
[22]. The pathophysiology and clinical significance of
normoalbuminuric renal impairment is a current matter
of debate.
In our study, the role of mild eGFR reduction in pre-
dicting the progression of kidney function decline ap-
pears to be remarkable. In fact, patients with eGFR <
90 ml/min/1.73 m2 show a constant and progressive
increased risk to develop stage > 3 CKD as comparedto patients with eGFR > 90 ml/min1.73 m2; the former
presented 80% increased risk to develop eGFR < 60 ml/
min for each 5 ml/min of eGFR decline. Although
we’ve found that eGFR < 90 ml/min/1.73 m2 is an inde-
pendent predictor for low eGFR (i.e. eGFR < 60 ml/
min/1.73 m2), when we looked at the eGFR loss > 30%
than baseline, it seemed to be protective as compared
to patient with eGFR > 90 ml/min/1.73 m2 (Table 3).
This finding is in line with data recently reported by
Bjornstad and co-workers who studied a selected sub-
set of 308 patients recruited from the Coronary Artery
Calcification in Type 1 Diabetes (N = 210) and the
Pittsburgh Epidemiology of Diabetes Complications
studies (N = 98). The authors found that early renal
function decline (defined as an annual loss of eGFR ≥3
ml/min/1.73 m2), which is an independent predictor of
overt nephropathy, was associated with greater base-
line eGFR levels. This finding was consistent across the
Fig. 3 a Study patients stratified by baseline eGFR (> 90 mL/min/1.73m2/60-90 mL/min/1.73m2) and albuminuria (Alb+/Alb-); b Odd ratios of
developing the composite renal endpoint over 4-year study period among different groups of patients
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effect of hyperfiltration on microalbuminuria development
in patients with T1DM was reported by Ficociello and co-
workers at Joslin Diabetes Center [28]. On the contrary,
Chiarelli and co-workers found that hyperfiltration pre-
dicted microalbuminuria over a 10-year follow-up in chil-
dren and young adults with T1DM [29]. Finally, a meta-
analysis aiming to unravel the role of hyperfiltration on dia-
betic nephropathy onset, concluded that individual with
hyperfiltration are at increased risk of progression to dia-
betic nephropathy [30]. However, most of the knowledge
on the mechanisms of hyperfiltration on the kidney come
from animal models [31]. In those studies, hyperfiltration
produces an increased glomerular pressure and a reduced
flow, both mechanisms starting kidney damage [32, 33]. Al-
though the underlying pathophysiological mechanism link-
ing hyperfiltration and kidney function loss is not
completely understood, the role of increased intraglomeru-
lar pressure associated to hyperfiltration could have a sig-
nificant role [34]. Indirect information coming from renalprotective effect of new antihyperglycemic drugs such as
sodium-glucose cotransporter-2 seem to support this
view [35].
The risk of developing stage > 3 CKD was inde-
pendent of albuminuria, although it raised signifi-
cantly to 8.2 times when albuminuria was present.
This finding emphasizes the significant and inde-
pendent role of mild eGFR reduction in inducing > 3
CKD, even though the presence of albuminuria en-
tails an adjunctive risk.
In line with our finding, Caramori and co-workers [8]
have shown that normoalbuminuric patients with
long-standing type 1 diabetes (particularly females with
retinopathy and/or hypertension), with reduced mea-
sured GFR defined as < 90ml/min/ 1.73 m2, had worse
diabetic glomerulopathy lesions than patients with simi-
lar duration of diabetes and normal or increased GFR,
suggesting that careful GFR measurements may be indi-
cated in normoalbuminuric patients, especially females
with hypertension and retinopathy.
Fig. 4 Estimated worsening rate of renal function at any given baseline eGFR
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first ones, the follow-up duration is relatively short,
although the mean age of patients (i.e. 45 ± 14 years)
and long duration of disease (i.e. 18 ± 12 years)
allowed us to develop significant number of renal
events. Second, laboratory measures, including serum
creatinine, were not measured in a single, centralized
laboratory. This could lead to some variability (i.e.
GFR). Moreover, albuminuria has been gathered only
as a categorical trait, possibly contributing to variabilityFig. 5 Multivariate OR for the incidence of stage ≥3 in patients with a give
albuminuria and eGFR> 90 (dashed line OR = 1)of the outcome measure. Furthermore, follow-up data
were available for the majority, but not all patients. Thus,
the generalization of our findings should be cautious, as
mortality from competitive risk was not positively col-
lected in the missing subgroup.
On the other hand, the large sample-size and the
homogeneous clinical features of patients, as well as the
representative geographical distribution of the recruiting
centers, contribute to a good representation of Italian
real life clinical conditions.n baseline eGFR and without albuminuria vs 411 patients with
Mirijello et al. BMC Nephrology          (2018) 19:347 Page 9 of 12Conclusions
Our data support the view that mild GFR reduction
in patients with T1DM may be useful predictor of
progression of GFR decline. Thus, microalbuminuria
alone may not provide optimal identification of pa-
tients with T1DM at higher risk of renal impairment,
measurements or estimation of GFR and identifica-
tion of other risk factors will be surely useful.
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